Evidence map›Paper›PMID 36831526›Full record

ArticleCancers2023

CD39-Expressing CD8

Meitong Liu, Yaning Zhao, Zhuoyun Xiao, Rongmiao Zhou, Xiaodong Chen, Saijin Cui, Shiru Cao, Xi Huang, Tianyu Chen, Xiangran Huo and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Terminally exhausted CD8Frontiers in immunology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Meitong LiuCancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Yaning ZhaoCancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Zhuoyun XiaoCancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Rongmiao ZhouCancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Xiaodong ChenCollege of Public Health, Hebei Medical University, Shijiazhuang 050031, China.
Saijin CuiCancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Shiru CaoCancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Xi HuangCancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Tianyu ChenCancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Xiangran HuoCancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Guoqiang ZhangDepartment of Dermatology, The First Hospital of Hebei Medical University, Shijiazhuang 050000, China.ORCID 0000-0002-4132-1690
Ziqiang TianDepartment of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.
Na WangCancer Institute, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China.ORCID 0000-0002-2574-9515
Hebei Medical University · CN

Funding

the 2020 Funding Program for the Introduction of Overseas Chinese Scholars c20200352the Key R&D Program of Hebei Province 213777105D
6 · The paper itself

Abstract

We aimed to explore the effect of CD39 expression on CD8

Indexed as

CD39+CD8+ T cellsdiagnosisesophageal squamous cell carcinomanomogramprognosistumor microenvironment

Identifiers

PMID36831526
PMCPMC9954671
OpenAlexW4320492326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.